Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1994-10-17
1997-01-14
Fleisher, Mindy
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424614, 424641, 514769, 514959, 530351, A61K 4505, A61K 3820, A61K 3330, C07K 1455
Patent
active
055936725
ABSTRACT:
A method is provided for increasing and maintaining the quantity and activity of immune leukocyte effector cells in preparation for lymphokine and cytokine administration before and during treatment for disease pathogens. The method simultaneously up-regulates the expression of high affinity IL-2 receptors on the above mentioned cells, making them receptive to subsequent IL-2 administration, which activates and directs these cells to mediate cytotoxic activity against disease pathogens. The method may also be employed in conjunction with the administration of other lymphokines, cytokines, biological response modifiers and pharmacological compounds whose activity would benefit from an increase in effector cells. The preferred method of administration is by inhalation of a zinc oxide fume or particulate from 15 to 900 mg ZnO/m.sup.3 for one or more exposures per day, one hour or less per exposure.
REFERENCES:
patent: 4946688 (1990-08-01), Fahim
patent: 5071658 (1991-12-01), Fahim
patent: 5409905 (1995-04-01), Eby, III
S. A. Rosenberg et al., "Treatment of Patients with Metastatic melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2", J. of Natl. Cancer Inst., vol. 86, No. 15, Aug. 3, 1994.
K. A. Smith "Interleukin-2", Sci. Amer., pp. 50-57, Mar. 1990.
R. C. Stein, "Immunomodulatory Agents: the Cytokines", European J. of Cancer, vol. 30A, No. 3, pp. 400-404, (1994).
C. C. Sturgis et al., "Metal Fume Fever: I. Clinical Observations on the Effect of the Experimental Inhalation of Zinc Oxide by Two Apparently Normal Persons", J. of Indus. Hygiene, vol. 9, No. 3, pp. 88-97, Mar. 1927.
M. Sznol et al., "Chemotherapy Drug Interactions with Biological Agents", Seminars in Oncology, vol. 20, No. 1, pp. 80-93, Feb. 1993.
Y. Tanaka et al., "Role of Zinc in Interleukin 2 (IL-2) Mediated T-Cell Activation", Scand. J. Immunol., vol. 31, pp. 547-552, (1990).
"Criteria for a Recommended Standard-Occupational Exposure to Zinc Oxide", National Institute for Occupational Safety and Health, Rockville, MD, (1975).
"Investigational Brochure Information for Investigators Proleukin Recombinant Interleukin-2 (HUMAN)", Cetus Oncology Division, Chiron Corporation, pp. 1-48, Jun. 2, 1992.
"Oral Zinc and Immunoregulation: A Nutritional or Pharmacological Effect of Zinc Supplementation?", Nutrition Reviews, vol. 40, No. 3, Mar. 1982.
"Occupational Health Guideline for Zinc Oxide Fume" U.S. Department of Health and Human Services Sep. 1978.
"Recommended Standard--for Occupational Exposure to Zinc Oxide", U.S. Department of Health, Education, and Welfare.
"The Researcher", The newsletter of the Cancer Research Institute, vol. 1, No. 2, Spring 1994.
"Zinc and Zinc Oxide" National Safety Council, Nov. 12, 1986.
P. Blanc et al., "An experimental Human Model of Metal Fume Fever", Annals of Internal Medicine, vol. 114, pp. 930-036, (1991).
R. K. Chandra, "Excessive Intake of Zinc Impairs Immune Responses", JAMA, vol. 252, No. 11, pp. 1443-1446, Sep. 21, 1984.
J. Chehimi et al., "Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from Both Healthy Donors and Human Immunodeficiency Virus-Infected Patients", J. Exp. Med., vol. 175, pp. 789-796, Mar. 1992.
M. Clerici et al., "Restoration of HIV-Specific Cell-Mediated Immune Responses by Interleukin-12 in Vitro", Science, vol. 262, pp. 1721-1724, Dec. 10, 1993.
J. Cohen, "T Cell Shift: Key to AIDS Therapy?", Science, vol. 262, pp. 175-176, Oct. 8, 1993.
P. Drinker et al., "Metal Fume Fever: II Resistance Acquired by Inhalation of Zinc Oxide on Two Successive Days", J. of Industrial Hygiene, vol. 9, No. 3, pp. 98-108, Mar. 1927.
P. Drinker et al., "Metal Fume Fever: IV. Threshold Doses of Zinc Oxide, Preventive Measures, and the Chronic Effects of Repeated Exposures", J. of Industrial Hygiene, vol. 9, No. 3, pp. 331-345, Mar. 1927.
P. J. Fraker et al., "Interrelationships between zinc and immune function", Federation Proceedings, vol. 45, No. 5, pp. 1474-1479, Apr. 1985.
E. A. Hamdi, "Chronic exposure to zinc of furnace operators in a brass foundry", Brt. J. Industr. Med., vol. 26, pp. 126-134, (1969).
E. Huland et al., "Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma", J. or Urology, vol. 147, pp. 344-348, Feb. 1992.
E. Huland et al., "Inhaled Interleukin-2 in Combination with low Dose Systemic Interleukin-2 and Interferon-.alpha. in Patients with Pulmonary Metastatic Renal-Cell Carcinoma: Effective and Toxicity of Mainly Local Treatment", Department of Urology, University Clinic Eppendork, pp. 1-29.
F. Nakajima et al., "Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression", Proc. Natl. Acad. Sci., vol. 91, pp. 7889-7893, Aug. 1994.
S. A. Rosenberg et al., "Treatment of 283 Consecutive Patients with Metastatic Melanoma or Renal Cell Cancer using Hig-Dose Bolus Interleukin 2", JAMA, vol. 271, No. 12, pp. 907-913, Mar. 1994.
Degen Nancy J.
Fleisher Mindy
LandOfFree
Method of preparing and maintaining the immune system for lympho does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preparing and maintaining the immune system for lympho, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preparing and maintaining the immune system for lympho will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1386128